Sanofi rachète ab science....

Published Sept. 18, 2020

POST SHARE TWEET

Dive Brief:An anti-inflammatory medicine from Roche appeared to help keep people hospitalized with COVID-19 associated pneumonia from needing intensive breathing support in a clinical study, the Swiss drugmaker claimed Friday in a surprise result that goes against prior clinical trial results.Treatment with Roche's drug, called Actemra, reduced the likelihood study participants would progress to mechanical ventilation or death by 44% when compared to placebo. Roche said it plans to discuss the data with regulators in the U.S. and abroad.But the study didn't show Actemra helped more patients live, nor did treatment appear to hasten discharge from hospital. Prior to Friday's results, Actemra had failed to show a benefit in a different COVID-19 study testing the drug in a similar setting. Sanofi and Regeneron recently gave up on testing Kevzara, which works similarly to Actemra, after disappointing data.

Plusieurs bios sont sur la sep....

Exemple geneuro aussi etc etc.....

La manipulation boursière coûte très cher juridiquement.....

Ou et quand parle t il de ab science.....??

Il n y a que Sanofi a ne pas être au courant....😂😂😂

Volume 67 000 de titres échangés je pense que 13 vents et jp n ont pas vraiment mesuré la news des forums.....

énièmes éditions.........😂😂😂